Ignite Creation Date:
2025-12-24 @ 11:49 PM
Ignite Modification Date:
2026-01-10 @ 2:36 PM
Study NCT ID:
NCT07120451
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-08-13
First Post:
2025-08-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker
Sponsor:
Fudan University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-10-10
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-10-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-10-31
Completion Date Type:
ESTIMATED
First Submit Date:
2025-08-06
First Submit QC Date:
None
Study First Post Date:
2025-08-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-06
Last Update Post Date:
2025-08-13
Last Update Post Date Type:
ACTUAL